<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of drug-susceptible tuberculosis in children&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of drug-susceptible tuberculosis in children<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of drug-susceptible tuberculosis in children<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="40%"></colgroup><colgroup span="4" width="15%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="3">Diagnostic category, regimens, and indications</td> <td class="subtitle1" colspan="4"><span class="nowrap_whitespace">Regimen*<sup>¶</sup><sup>Δ</sup></span></td> </tr> <tr> <td class="subtitle2" colspan="2">Intensive phase</td> <td class="subtitle2" colspan="2">Continuation phase</td> </tr> <tr> <td class="subtitle3">Regimen</td> <td class="subtitle3">Duration</td> <td class="subtitle3">Regimen</td> <td class="subtitle3">Duration</td> </tr> <tr> <td class="highlight_sub4_gray_text" colspan="5"><strong class="heading">Pulmonary TB: drug susceptible (presumed or confirmed)</strong></td> </tr> <tr> <td class="indent1"><strong>Traditional 6-month regimen (daily)</strong><sup>[2]</sup> <ul class="decimal_heading"> <li>New smear-positive pulmonary TB</li> <li>New smear-negative pulmonary TB with extensive parenchymal involvement</li> <li>Severe concomitant HIV disease</li> </ul> </td> <td> <p>Isoniazid</p> <p>Rifampin</p> <p>Pyrazinamide</p> Ethambutol</td> <td>2 months</td> <td> <p>Isoniazid</p> Rifampin</td> <td>4 months</td> </tr> <tr> <td class="indent1"><strong>Shortened 4-month traditional regimen (daily)</strong> <ul class="decimal_heading"> <li>Age 3 months to &lt;16 years</li> <li>Nonsevere, smear-negative pulmonary TB</li> </ul> </td> <td> <p>Isoniazid</p> <p>Rifampin</p> <p>Pyrazinamide</p> Ethambutol (use according to local guidance)</td> <td>8 weeks</td> <td> <p>Isoniazid</p> Rifampin</td> <td>8 weeks</td> </tr> <tr> <td class="indent1"><strong>Rifapentine-moxifloxacin-based regimen (daily)</strong> <ul class="decimal_heading"> <li>Age ≥12 years, body weight ≥40 kg</li> <li>Absence of extrapulmonary involvement</li> </ul> </td> <td> <p>Isoniazid</p> <p>Rifapentine</p> <p>Moxifloxacin</p> Pyrazinamide</td> <td>8 weeks</td> <td> <p>Isoniazid</p> <p>Rifapentine</p> Moxifloxacin</td> <td>9 weeks</td> </tr> <tr> <td class="highlight_sub4_gray_text" colspan="5"><strong class="heading">Extrapulmonary TB: drug susceptible (presumed or confirmed)</strong></td> </tr> <tr> <td class="indent1"><strong>Traditional 6-month regimen (daily)</strong> <ul class="decimal_heading"> <li>Severe forms of extrapulmonary TB (not including meningitis or osteoarticular disease)</li> <li>Less severe forms of extrapulmonary TB (may omit ethambutol)</li> </ul> </td> <td> <p>Isoniazid</p> <p>Rifampin</p> <p>Pyrazinamide</p> Ethambutol</td> <td>2 months</td> <td> <p>Isoniazid</p> Rifampin</td> <td>4 months</td> </tr> <tr> <td class="indent1"><strong>12-month regimen (daily)</strong> <ul class="decimal_heading"> <li>Meningitis</li> <li>Osteoarticular disease</li> </ul> </td> <td> <p>Isoniazid</p> <p>Rifampin</p> <p>Pyrazinamide</p> Ethambutol (or ethionamide or levofloxacin<sup>◊</sup>)</td> <td>2 months</td> <td> <p>Isoniazid</p> Rifampin</td> <td><span class="nowrap_whitespace">10 months<sup>[3]</sup></span></td> </tr> <tr> <td class="indent1"><strong>6-month intensive regimen (daily)</strong><sup>§</sup></td> <td> <p>Isoniazid</p> <p>Rifampin</p> <p>Pyrazinamide</p> Ethionamide</td> <td>6 months</td> <td> </td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>TB: tuberculosis; HIV: human immunodeficiency virus.</p>
<p>* For infants and young children, isoniazid tablets and can be pulverized, and the contents of rifampin capsules can be suspended in a flavored liquid or sprinkled on semisoft foods. Pyridoxine (vitamin B6) supplementation is not routinely recommended for children receiving isoniazid but should be considered for exclusively breastfed infants, malnourished children or those with diets poor in pyridoxine, and children with HIV infection. The isoniazid/B6 suspension (available in the United States) uses a sorbitol base that can induce diarrhea, especially at higher doses.</p>
<p>¶ Direct observation of drug administration is strongly recommended.</p>
<p>Δ Refer to separate UpToDate tables for drug dosing.</p>
<p>◊ While ethambutol is recommended by the World Health Organization as the fourth drug to be used in this regimen, in practice, ethionamide or levofloxacin is used more commonly.</p>
§ In children and adolescents with bacteriologically confirmed or clinically diagnosed TB meningitis (without suspicion or evidence of multidrug-resistant/rifampin-resistant-TB), the World Health Organization has endorsed a 6-month intensive regimen as an alternative option to the 12-month regimen.</div><div class="graphic_reference">References:
<ol>
<li>WHO Operational Handbook on Tuberculosis. Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization, 2022. <a href="https://www.who.int/publications/i/item/9789240046832" target="_blank">https://www.who.int/publications/i/item/9789240046832</a> (Accessed on May 23, 2023).</li>
<li>American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021.</li>
<li>Rapid Advice: Treatment of tuberculosis in children. World Health Organization, 2010. Available at: <a href="https://apps.who.int/iris/handle/10665/44444" target="_blank">https://apps.who.int/iris/handle/10665/44444</a> (Accessed on May 25, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 50271 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
